Abbott Labs's most recent trend suggests a bullish bias. One trading opportunity on Abbott Labs is a Bull Put Spread using a strike $42.00 short put and a strike $37.00 long put offers a potential 5.49% return on risk over the next 24 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $42.00 by expiration. The full premium credit of $0.26 would be kept by the premium seller. The risk of $4.74 would be incurred if the stock dropped below the $37.00 long put strike price.
The 5-day moving average is moving up which suggests that the short-term momentum for Abbott Labs is bullish and the probability of a rise in share price is higher if the stock starts trending.
The 20-day moving average is moving up which suggests that the medium-term momentum for Abbott Labs is bullish.
The RSI indicator is at 62.55 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Abbott Labs
Abbott Introduces New Similac® Breastfeeding Supplement with DHA, Lutein and Vitamin E
Thu, 24 Jul 2014 12:00:00 GMT
PR Newswire – Abbott (ABT), the makers of Similac® and experts in infant nutrition for nearly 90 years, studied the diets of more than 80 lactating women to assess how their nutritional intake compared to dietary recommendations. The research found few lactating women consistently consume enough key nutrients, like DHA, lutein and vitamin E, through their diet. Abbott's new Similac Breastfeeding Supplement is specially designed to enhance the levels of DHA, lutein and vitamin E in breast milk. The supplement should be taken with a prenatal vitamin or multivitamin to help fill moms' dietary gaps.
GlaxoSmithKline Slumps: GSK Falls 5.9% in Session
Thu, 24 Jul 2014 10:54:12 GMT
Who gets the last word on Obamacare?
Wed, 23 Jul 2014 14:23:33 GMT
CNBC – After a split ruling on Obamacare from the courts, who gets the last word? Law professor Dan Eaton weighs in.
Dividend Growth Investing: An Open Portfolio For Your Review
Tue, 22 Jul 2014 21:30:00 GMT
India's new government vows clampdown on healthcare graft
Tue, 22 Jul 2014 17:32:10 GMT
Reuters – India's health minister called for tougher laws on Tuesday after a media report alleged that laboratories had offered kickbacks to doctors who referred patients to their diagnostic centres. Harsh Vardhan has lashed out several times in recent days against bribery in the $74 billion healthcare sector, signalling that the new government will make tackling the corruption that blighted the outgoing administration a priority. An undercover investigation by Hindi news channel News Nation that ran on Monday showed footage purportedly of reputed private laboratories offering commissions as high as 50 percent to doctors who referred patients to their diagnostic centres. With about 40,000 laboratories in India, the diagnostic market is the fastest growing segment of India's healthcare industry, according to PwC, with the segment forecast to grow to $17 billion by 2021 from $3.4 billion in 2011.
Also on Market Tamer…
Follow Us on Facebook